Interestingly, encouraging preliminary results for treatment with onartuzumab and rilotumumab, which are antibodies against hepatocyte growth factor, were reported for GEJ and gastric cancers with a high expression of c-MET in immunohistochemical analysis[28], leading to two Phase III trials that are currently open for accrual. This evidence concerns the gene HGF and gastric cancer.